Updates are available Correction dated 2021-09-08
Click to view Correction: https://doi.org/10.1038/s41598-021-96915-2
Updates are available Correction dated 2022-01-18
Click to view Correction: https://doi.org/10.1038/s41598-022-05488-1
-
Authors
Lauko, Adam
Thapa, Bicky
Sharma, Mayur
Muhsen, Baha’eddin
Barnett, Addison
Rauf, Yasmeen
Borghei-Razavi, Hamid
Tatineni, Vineeth
Patil, Pradnya
Mohammadi, Alireza
Chao, Samuel
Murphy, Erin S.
Angelov, Lilyana
Suh, John
Barnett, Gene H.
Nowacki, Amy S.
Pennell, Nathan
Ahluwalia, Manmeet S.
- License Information
-
More Information
Article History
Received: 9 September 2020
Accepted: 6 January 2021
First Online: 5 April 2021
Change Date: 18 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-022-05488-1
Change Date: 8 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-96915-2
Competing interests
: Ahluwalia: Receipt of grants/research supports: Astrazeneca, Abbvie, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Merck. Stock shareholder: Doctible, Mimivax. Receipt of honoraria or consultation fees: Elsevier, Wiley, Abvvie, VBI Vaccines, Bayer, karyopharm, Tocagen, Forma therapeutics. Chao: Honorarium from Varian Medical Systems and stock in Merck. Pennell: Consulting/advisory for BMS, Merck, Astrazeneca, Eli Lilly, Inivata. Barnett: consultant for Monteris Medical Inc, royalty interests for Roche. Mohammadi: consultant for Monteris Medical Company. Suh: consultant for Abbvie. No conflict of interests exists for remaining authors.
